Sigyn Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

STOCK TRANSACTIONS (Details Narrative)

STOCK TRANSACTIONS (Details Narrative) - USD ($)			1 Months Ended				2 Months Ended
STOCK TRANSACTIONS (Details Narrative) - USD ($)	Jul. 14, 2017	Jun. 30, 2017	Mar. 31, 2018	Jan. 31, 2018	Mar. 31, 2017	Mar. 17, 2017	Feb. 28, 2018	Dec. 31, 2017	May 19, 2017
Preferred stock cancellation term						10 years
Common stock payable			$ 156,656					$ 79,625
Preferred stock value
Mr. Joseph Segelman [Member]
Preferred stock value									$ 270,000
Restricted Stock [Member] \| Outside Consultant [Member]
Number of shares issued	487,500		568,750
Value of shares issued	$ 34,125		$ 101,156
Common stock payable								$ 101,156
Restricted Stock [Member] \| Secured Promissory Note [Member] \| Alpha Capital Anstalt [Member]
Number of shares issued		1,500,000
Value of shares issued		$ 105,000
Brio Capital Master Fund Ltd. [Member] \| Secured Promissory Note [Member] \| Alpha Capital Anstalt [Member]
Principle amount		$ 1,125,000
Number of shares issued			600,000
Brio Capital Master Fund Ltd. [Member] \| Restricted Stock [Member] \| Secured Promissory Note [Member] \| Alpha Capital Anstalt [Member]
Number of shares issued					600,000
Value of shares issued					$ 55,500
Crossover Capital Fund II, LLC \| Securities Purchase Agreement [Member]
Value of shares issued							$ 294,000
Crossover Capital Fund II, LLC \| CommonStock \| Securities Purchase Agreement [Member]
Number of shares issued							833,332
Crossover Capital Fund II, LLC \| Redeemable Shares \| Securities Purchase Agreement [Member]
Number of shares issued							3,000,000
Crossover Capital Fund II, LLC \| Restricted Stock [Member] \| Securities Purchase Agreement [Member]
Number of shares issued				2,395,650
Value of shares issued				$ 263,522
Crossover Capital Fund II, LLC \| Warrants \| Securities Purchase Agreement [Member]
Number of shares issued							1,960,000
Value of shares issued							$ 255,000